Day One Net Worth
Day One Net Worth Breakdown | DAWN |
Day One Net Worth Analysis
Day One's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Day One's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Day One's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Day One's net worth analysis. One common approach is to calculate Day One's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Day One's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Day One's net worth. This approach calculates the present value of Day One's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Day One's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Day One's net worth. This involves comparing Day One's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Day One's net worth relative to its peers.
Enterprise Value |
|
To determine if Day One is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Day One's net worth research are outlined below:
| Day One Biopharmaceu generated a negative expected return over the last 90 days | |
| Day One Biopharmaceu has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (188.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Day One Biopharmaceuticals currently holds about 394.86 M in cash with (146.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38. | |
| Day One Biopharmaceu has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research ... |
Day One uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Day One Biopharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Day One's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Day One's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Day One is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Day One Biopharmaceuticals backward and forwards among themselves. Day One's institutional investor refers to the entity that pools money to purchase Day One's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.9 M | Hhg Plc | 2024-06-30 | 1.8 M | Timessquare Capital Management, Llc | 2024-09-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 1.3 M | Vestal Point Capital Lp | 2024-06-30 | 1.2 M | Maverick Capital Ltd | 2024-06-30 | 1.2 M | Boxer Capital Llc | 2024-09-30 | 1.2 M | First Turn Management Llc | 2024-09-30 | 947.9 K | Ra Capital Management, Llc | 2024-06-30 | 7.9 M | Fmr Inc | 2024-09-30 | 7.4 M |
Follow Day One's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.37 B.Market Cap |
|
Project Day One's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (0.55) | (0.52) |
When accessing Day One's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Day One's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Day One's profitability and make more informed investment decisions.
Evaluate Day One's management efficiency
Day One Biopharmaceu has return on total asset (ROA) of (0.2543) % which means that it has lost $0.2543 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1784) %, meaning that it created substantial loss on money invested by shareholders. Day One's management efficiency ratios could be used to measure how well Day One manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.62. At this time, Day One's Net Tangible Assets are very stable compared to the past year. As of the 21st of November 2024, Non Currrent Assets Other is likely to grow to about 263.7 K, while Total Assets are likely to drop about 239.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.34 | 4.56 | |
| Tangible Book Value Per Share | 4.34 | 4.56 | |
| Enterprise Value Over EBITDA | (4.53) | (4.76) | |
| Price Book Value Ratio | 3.36 | 3.53 | |
| Enterprise Value Multiple | (4.53) | (4.76) | |
| Price Fair Value | 3.36 | 3.53 | |
| Enterprise Value | 934.3 M | 1.3 B |
Effective management at Day One has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue 8.0209 | Revenue 102 M | Revenue Per Share 1.144 | Return On Equity (0.18) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Day One insiders, such as employees or executives, is commonly permitted as long as it does not rely on Day One's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Day One insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Day One Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Day One Earnings per Share Projection vs Actual
Day One Corporate Management
| PharmD Chiodin | Chief Officer | Profile | |
| Jaa Roberson | Chief Officer | Profile | |
| Elly MD | Chief Officer | Profile | |
| Adam Dubow | General Counsel | Profile | |
| Lauren MBA | Chief Officer | Profile | |
| Adam JD | General Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.